CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (AMEX: IDP) today reported financial results for the three and nine months ended September 30, 2007. “Idera expanded its scientific leadership in Toll-like Receptor (TLR) research during the third quarter. We reported encouraging preclinical findings with TLR agonists and antagonists, prepared to initiate combination studies with IMO-2055 in oncology, and initiated a phase 1 trial evaluating IMO-2125, our second TLR9 agonist, in hepatitis C. In addition, we continued to strengthen our intellectual property portfolio with the issuance of two key patents for immune stimulatory oligonucleotides and provided support in our ongoing collaborations with Novartis and Merck & Co., Inc.,” said Sudhir Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer of Idera.
